Deutsche Bank AG reaffirmed their buy rating on shares of Indivior PLC (LON:INDV) in a report issued on Tuesday. The firm currently has a GBX 400 ($5.00) target price on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on INDV. Jefferies Group boosted their target price on shares of Indivior PLC from GBX 320 ($4.00) to GBX 330 ($4.12) and gave the stock a buy rating in a research report on Monday, August 1st. Numis Securities Ltd reissued a buy rating and set a GBX 370 ($4.62) target price on shares of Indivior PLC in a research report on Wednesday, August 17th. Stifel Nicolaus reissued a buy rating and set a GBX 350 ($4.37) target price on shares of Indivior PLC in a research report on Wednesday, August 17th. Royal Bank Of Canada lifted their price target on shares of Indivior PLC from GBX 185 ($2.31) to GBX 325 ($4.06) and gave the stock a sector performer rating in a research note on Tuesday, August 9th. Finally, Morgan Stanley lifted their price target on shares of Indivior PLC from GBX 280 ($3.50) to GBX 330 ($4.12) and gave the stock an overweight rating in a research note on Monday, August 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of GBX 369.29 ($4.61).

Shares of Indivior PLC (LON:INDV) traded up 1.18% during mid-day trading on Tuesday, reaching GBX 351.00. 2,225,438 shares of the company were exchanged. The firm’s market capitalization is GBX 2.53 billion. The company’s 50-day moving average is GBX 324.60 and its 200 day moving average is GBX 271.67. Indivior PLC has a 12 month low of GBX 126.60 and a 12 month high of GBX 377.00.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.

Receive News & Stock Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related stocks with our FREE daily email newsletter.